Aptevo Therapeutics (APVO) Non Operating Income (2015 - 2017)
Aptevo Therapeutics (APVO) posted Non Operating Income of -$588000.0 for Q4 2017, down 34.86% sequentially from -$436000.0 in Q3 2017, and down 49.62% YoY from -$1.2 million in Q4 2016.
Aptevo Therapeutics (APVO) Non Operating Income (2015 - 2017) Analysis & Trends
Aptevo Therapeutics has reported Non Operating Income for 3 years, with the latest figure at -$588000.0 in Q4 2017.
- Quarterly Non Operating Income fell 49.62% year-over-year to -$588000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was -$1.9 million (down 140.17% YoY) and the FY2017 annual result came in at -$1.9 million, down 140.0% from the prior year.
- Non Operating Income fell to -$588000.0 in Q4 2017 per APVO's latest filing, from -$436000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $84000.0 in Q3 2015 and troughed at -$588000.0 in Q4 2017.
- A 3-year average of -$244818.2 and a median of -$393000.0 in 2016 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2016 and 2017: Non Operating Income soared 77.78% in 2016, then tumbled 12725.0% in 2017.
- Over 3 years, Non Operating Income stood at -$7000.0 in 2015, then plunged by 5514.29% to -$393000.0 in 2016, then tumbled by 49.62% to -$588000.0 in 2017.
- According to Business Quant data, Non Operating Income over the past three periods registered -$588000.0, -$436000.0, and -$513000.0 for Q4 2017, Q3 2017, and Q2 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -588,000.00 |
| Sep 30, 2017 | -436,000.00 |
| Jun 30, 2017 | -513,000.00 |
| Mar 31, 2017 | -406,000.00 |
| Dec 31, 2016 | -393,000.00 |
| Sep 30, 2016 | -492,000.00 |
| Jun 30, 2016 | -4,000.00 |
| Mar 31, 2016 | 80,000.00 |
| Dec 31, 2015 | -7,000.00 |
| Sep 30, 2015 | 84,000.00 |
| Jun 30, 2015 | -18,000.00 |